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ditis
We report herein the case of a prosthetic valve endocarditis
due to Kytococcus schroeteri.
A 70-year-old man with a bioprosthetic valve was
admitted to Laveran Hospital in Marseilles, France in Sep-
tember 2004 with a fever (39 8C), headache, and cough.
Blood cultures were sterile. He was treated with vancomycin
and gentamicin for four weeks. We were unable to recover
any further details about this period.
In March 2005 he was admitted to Timone Hospital in
Marseilles for a new episode of fever and shivers. On admis-
sion, his white blood cell count was 11.53  109/l (80.8%
polymorphonuclear cells), his hemoglobin level was 13.1 g/dl, the erythrocyte sedimentation rate was 24 mm in the first
hour, and his C-reactive protein level was 83 mg/l. Transe-
sophageal echocardiography showed a 4-mm vegetation on
the aortic bioprosthetic valve and an intertrigonal abscess
(Figure 1). Computed tomography examination showed an
embolic cerebral stroke and bilateral renal emboli.
An endocarditis diagnostic kit was performed, as pre-
viously described.1 The first blood culture of the kit was
performed using a set of Bactec1 Plus Aerobic/F and Bactec1
Lytic/10 Anaerobic/F bottles (BD Diagnostic Systems, Sparks,
MD, USA). The specimen volume is 10 ml for each bottle. The
second and third blood cultures of the kit were collected in
Bactec Plus Aerobic/F bottles, with 2-h intervals between
samples. Blood bottles were incubated for 5 days at 37 8C
under continuous automated monitoring for bacterial growth
in the medium. One blood culture grew Gram-positive cocci.
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Figure 1 Transesophageal echocardiography in 1208 view showing an intertrigonal abscess and an aortic bioprosthesis vegetation.
Ao = aorta, LA = left atrium, LV = left ventricle.Subcultures were plated on blood agar and chocolate agar
(BioMerieux, Marcy l’Etoile, France) and incubated aerobi-
cally at 37 8C with 5% CO2. The microorganism was identified
as Micrococcus luteus by biochemical tests using the minia-
turized API Staph strip (BioMerieux, Marcy-l’Etoile, France).
The isolate was susceptible to rifampin, co-trimoxazole,
gentamicin, vancomycin, and teicoplanin, and resistant to
ofloxacin and oxacillin. The identifiedM. luteuswas regarded
as a contaminant and the patient was empirically treated
with intravenous amoxicillin 2 g every 4 hours for six weeks,
and gentamicin 3 mg/kg/day once a day for two weeks. TheFigure 2 Phylogenetic tree of representatives of the genus Kyto
comparison (1435-nt fragment). Gene sequences were aligned u
Phylogenetic relationships with closely related species were det
determined following the assumptions described by Kimura and we
method. Numbers at nodes are proportions of 100 re-samplings that s
as the outgroup. Bar, 0.01 nucleotide change per nucleotide positioresults of the other tests performed in the endocarditis
diagnostic kit remained negative.
In June 2005, repeated physical examination and repeat
echocardiography revealed an aortic insufficiency, a false
aneurysm, and a paraprosthetic leak. The vegetation had
disappeared. The patient was readmitted to the hospital and
the aortic bioprosthetic valve was replaced. Blood culture
and bacterial culture of the valve were sterile. Histologic
examination of the removed valve was consistent with the
diagnosis of infectious endocarditis, which was finally
strengthened.coccus and relative bacteria inferred from 16S rDNA sequence
sing the multisequence alignment program CLUSTAL X (1.8).
ermined by using MEGA version 2.1. Distance matrices were
re used to elaborate a dendrogram using the neighbor-joining
upport the topology shown. Corynebacterium striatum was used
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Table 1 Reported cases of Kytococcus schroeteri endocarditis
Patient
[reference]
Age/sex Valve Duration between
valve replacement
and onset
Duration between
onset and beginning
of efficient treatment
Microbiological diagnosis Type of
treatment
Outcome of
treatment
Patient 1 [3] ? ? ? ? First report naming
this organism
? ?
Patient 2 [4] 34/F Aortic prosthetic
valve
10 weeks Immediate 16S rDNA sequencing Vancomycin, gentamicin
and rifampin for 21 days
Improved
Patient 3 [5] 73/M Aortic bioprosthesis 3 years Immediate 16S rDNA sequencing
and analysis of the
fatty acid contents
Intravenous vancomycin
(2 g/day) and gentamicin
(240 mg/day) for 3 weeks,
then gentamicin and
rifampin for 3 weeks
Improved
Patient 4 [6] 49/F Mitral prosthetic
valve
10 years Immediate 16S rDNA sequencing Vancomycin—gentamicin,
then pristinamycin—
vancomycin for 6 weeks,
followed by rifampin—
pristinamycin for 3 weeks
Improved
Patient 5
(present study)
70/M Aortic bioprosthesis 26 months 9 months 16S rDNA sequencing Intravenous vancomycin
(30 mg/kg/day) and
gentamicin (3mg/kg/day)
for 6 weeks
Improved
226 CorrespondenceWe performed 16S rDNA amplification and sequencing on
valvular tissue. The MagNA Pure LC DNA isolation kit II (tissue)
with the MagNA Pure LC instrument was used to extract DNA
from the valvular tissue. Amplification was performed as
previously described using fD1 and rp2 primer pair.2 PCR
products were purified using MultiScreen PCR plates (Milli-
pore, Molsheim, France), and sequencing reactions were
carried out using a DNA sequencing kit (BigDye Terminator
v. 1.1 cycle sequencing kit; PE Biosystems, Foster City, CA,
USA). Sequence products were purified and electrophoresis
was performed with the 3100 Genetic Analyzer (Applied
Biosystems, Courtaboeuf, France). We obtained a 1445-bp
sequence. When compared to the GenBank database, it was
found to differ at only one nucleotide position from that of K.
schroeteri (GenBank accession number AJ297722).
Because of this unusual result, we decided to identify the
M. luteus isolated from blood cultures in March 2005, which
had been preserved, using 16S rDNA sequencing. DNA from
the isolated strain was extracted and amplified as described
above. Negative PCR controls remained negative. Subse-
quently, from both the isolate from the previous blood
culture and from the replaced cardiac valve DNAs, we
obtained identical 1445-bp nucleotide sequences. This
sequencewas deposited in GenBank under accession number
DQ358755. The patient was treated with intravenous van-
comycin 30 mg/kg/day for six weeks, and gentamicin 3 mg/
kg/day for two weeks. He improved rapidly. These results
were strictly controlled before assessing the unusual diag-
nosis of endocarditis caused by K. schroeteri. It was there-
fore a difficult diagnosis since the patient was treated
sequentially in two different hospitals. Furthermore several
empiric treatments were responsible for a lack of clinical
symptoms that implied a biological and echographic follow-
up.
To the best of our knowledge, there are only four previous
clinical reports of endocarditis caused by K. schroeteri3—6
(Table 1). In the first report naming this organism,3 the
isolates were obtained from blood specimens of a patient
with endocarditis, suggesting a possible disease association.
In the second report,4 K. schroeteri endocarditis developed
in a patient 3 months after she underwent cardiac surgery,
suggesting perioperative contamination. In the third case
report,5 the authors described a subacute endocarditis that
developed 3 years after surgery, which is more likely to have
been caused by hematogenous spread. In the fourth case,6
the patient underwent a valve replacement 10 years prior to
the evaluated infection and presented with a subacute fever.
In the present case, endocarditis developed two and a half
years after cardiac surgery and presented as a subacute
evolution. No source of contamination was evident. Initially,
the microorganism was not found in blood cultures. Then,
when cultivated, it was phenotypically identified asM. luteus
in one out of three blood cultures, and was initially consid-
ered to be a contaminant, since the isolate grew only once
and only in one out of three blood cultures.
Results performed using phenotypic identification systems
should be interpreted with caution if strictly aerobic micro-
cocci resistant to oxacillin are identified, which is an unusual
result. It appears important to take notice of isolates thought
to be contaminants when biochemical tests are unusual.
Commercialized phenotypic identification systems, such as
the miniaturized API Staph strips, are unable to identify K.schroeteri. Definitive identification should be performed
using molecular techniques.
The former genus Micrococcus has been subdivided into
four genera: Kocuria, Nesterenkonia, Kytococcus, and Derma-
coccus, followed by a rearrangement into two families (Micro-
coccaceae forKocuriaandNesterenkonia,Dermacoccaceae for
KytococcusandDermacoccus) of the suborderMicrococcineae7
(Figure 2). Kytococcus schroeteri is a newly discovered Gram-
positive actinobacterium originally described in 2002, isolated
from human blood. It presents as a Gram-positive coccus,
predominantly occurring singly, in pairs, tetrads, and occa-
sionally clusters. It is yellow-pigmented, strictly aerobic, non-
hemolytic, oxidase-negative, non-encapsulated, and non-
motile. It grows at 37 8C on Columbia agar supplemented with
5% sheep’s blood after 24 h of incubation.3 The route of
infection also remains unclear. A recent study on this subject
described several Gram-positive cocci, including Kytococcus
sedentarius but not K. schroeteri, as contaminants of human
skin and mucosa.8 Kytococcus schroeteri has only been
described five times as a human pathogen: once in a bactere-
mic pneumonia9 and four times in endocarditis.3—6
We report herein a fifth case of endocarditis and highlight
the role of this bacterium as a potential human pathogen,
specifically as an agent of prosthetic endocarditis. We would
also warn physicians that Micrococcus spp isolated from
clinical specimens might, in fact, be Kytococcus spp, espe-
cially if they are resistant to oxacillin. In conclusion, these
microorganisms should not be systematically considered as
part of the normal flora of human skin and mucosa.
Conflict of interest: No conflict of interest to declare.
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doi:10.1016/j.ijid.2007.06.011Epstein—Barr virus infection with acute pan-
creatitis
Epstein—Barr virus (EBV) infection occurs worldwide and
most commonly in early childhood and adolescence. Common
clinical presentations include infectious mononucleosis,
upper respiratory tract infection, diarrhea, and abdominal
complaints.1 We report a case of EBV infection with a rare
manifestation — acute pancreatitis — in an otherwise healthy
patient.
An 18-year-old female was admitted to our hospital with a
4-day history of high-grade fever, sore throat, vomiting,
abdominal pain, and decreased appetite. Her initial physical
examination revealed a temperature of 40.0 8C, a blood
pressure of 83/29 mmHg, mildly injected pharynx and ton-
sils, small bilateral shoddy non-tender cervical lymph nodes,
and generalized abdominal tenderness, especially at the
right upper quadrant area and epigastrium. Laboratory data
revealed a total white blood cell count of 1.9  109/l (66%
band neutrophils, 7% segmental neutrophils, 4% atypical
lymphocytes), hemoglobin of 11.0 g/dl, platelet count of
23  109/l, prothrombin time of 15.2 s, activated partial
thromboplastin time of 82 s, international normalized ratio
(INR) of 1.2, fibrinogen of 80 mg/dl, fibrin degradation pro-
ducts (FDP) of >40 mg/ml, D-dimer of >20 mg/ml, aspartate
aminotransferase of 181 U/l, alanine aminotransferase of
57 U/l, alkaline phosphatase of 97 U/l, total bilirubin of
7.4 mg/dl, amylase of 620 U/l (normal range: 60—180 U/l),
and lipase of 659 U/l (normal range: 0—160 U/l). Ultrasound
of the abdomen showed thickening of the anterior gallblad-
der wall without gallstones. Computed tomography (CT) of
the abdomen and pelvis revealed moderate gallbladder wall
thickening, pericholecystic fluid, edematous pancreas, and
hepatosplenomegaly. A hydroxy iminodiacetic acid (HIDA)
scan, however, did not suggest acute cholecystitis. The pre-
sumptive diagnosis was septic shock with acute pancreatitis
and disseminated intravascular coagulation (DIC). The dif-
ferential diagnoses include systemic viral infections or pri-
mary bone marrow disorders such as lymphoma or
lymphoblastic leukemia. Blood cultures and a urine culture
were taken, and empirical antibiotic therapy consisting ofaztreonam, clindamycin, and moxifloxacin was initiated
given the patient’s history of penicillin allergy. Concerning
her pancytopenia, bone marrow aspiration was performed
and revealed pancytopenia with dyshematopoiesis, increase
in mononuclear cells (approximately 15%), normal blast cell
population, and no evidence of granulomatous inflammation.
Four days after treatment the fever subsided with improve-
ment of abdominal signs. Blood cultures, urine culture, and
bonemarrow culture results were all negative. Viral hepatitis
profiles (A, B, C), HIV RNA, monospot test, and cytomegalo-
virus immunoglobulin M and G were all negative. The diag-
nosis of EBV infection was made by the positive result of EBV
immunoglobulin M and G (VCA, viral capsid antigen) and
immunophenotyping of the bone marrow lymphocytes
(CD4: 12%, CD8: 84%, CD4/CD8 ratio of 0.14 with increased
numbers of CD57-negative CD8 T cells and gamma delta T
cells) consistent with EBV infection. All antibiotics were
discontinued after 4 days of treatment. The patient recov-
ered uneventfully by day 7 after supportive treatment for
pancreatitis.
The gastrointestinal (GI) system is one of the most com-
mon organ systems affected by EBV. Nausea, vomiting, anor-
exia, and abdominal pain are frequently reported symptoms,
probably reflecting mild hepatitis, hepatomegaly, splenome-
galy, and rarely pancreatitis.2
Nine cases of primary EBV infection with pancreatitis have
been reported in the literature (Table 1). In these cases, the
onset of GI symptoms occurred at an average 12 days (range
4—42 days) after the onset of initial constitutional symptoms.
Serum amylase, urine amylase, and clinical presentations are
the important diagnostic tools for acute pancreatitis. Ima-
ging studies, such as CT or ultrasonography of the abdomen
can be used to confirm diagnosis if they are performed late
enough to see gross inflammatory changes of the pancreas.
Symptomatic and supportive treatment was used successfully
in all cases, and the overall outcomes of acute pancreatitis in
the setting of EBV infection were good.3—9
Ourpatient alsohadotherunusual clinical presentations for
EBV infection. Firstly, she presentedwith shockmost likely due
to dehydration and third space fluid loss from acute pancrea-
titis. Secondly, she developed DIC, which can be caused by
either pancreatitis or rarely, EBV itself. Thirdly, she had a
